Skip to content
lifestyle.projectdiaspora.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Immutep Limited
Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research
October 14, 2026
Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
October 13, 2026
Immutep Receives ~A$0.86 Million R&D Tax Incentive
September 30, 2026
Change to American Depositary Share Ratio
September 21, 2026
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
September 11, 2026
Immutep Quarterly Activities Report Q4 FY26
July 30, 2026
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
July 24, 2026
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
June 4, 2026
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
May 28, 2026
Immutep Quarterly Activities Report Q3 FY26
May 6, 2026
1
2
Next Page
→